Financial Analysis

COMMITMENTS AND CONTINGENCIES The Company is involved from time to time in various disputes, claims, and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amounts of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding its business which may result in adverse judgments, settlements, fines, penalties, injunctions, or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company has received subpoenas from time to time related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations, or other laws. The Company intends to defend its current litigation matters but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows. The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accru …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

EMPLOYEE DEFERRED SAVINGS PLAN The Company has a deferred savings plan which qualifies under Section 401(k) of the Internal Revenue Code. Substantially all of the Companys U.S. employees are covered by the plan. The Company makes matching contributions of 50.0% of each employees contribution with the employers contribution not to exceed 4.0% of the employees compensation. The Companys recorded contributions to the plan are as follows: Years Ended December 31, (in millions) 2025 2024 2023 Deferred savings plan contributions $ 10.4 $ 10.3 $ 10.0 …

CompensationAndEmployeeBenefitPlansTextBlock · excerpt; the full note is in the filing

"LONG-TERM DEBT The Company's long-term debt at December 31, 2025 consisted of the following amounts: Years Ended December 31, (in millions) 2025 2024 Long-term debt $ 125.0 $ 40.5 Accrued exit fee 3.8 Unamortized debt discount and issuance costs (8.9) (0.9) Total Long-term debt, net $ 119.9 $ 39.6 On July 31, 2025 (the ""Closing Date""), the Company entered into a Credit Agreement (the ""Credit Agreement"") with the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent (the ""Administrative Agent"") and as initial lender. The Credit Agreement consists of a $200 million term loan credit facility with an initial term loan of $125.0 million (the ""Initial Loan""), which amount was funded on the Closing Date, and delayed draw term loans (the ""Delayed Draw Loans"" and together with the Initial Loan, the ""Loans""), at the election of the Company, subject to the timing and terms specified in the Credit Agreement, on or prior to June 30, 2027, in a maximum principal amount of $75.0 million (the ""Credit Facility""). The Company incurred debt discounts and issuance costs totaling $9.4 million. These costs are being amortized using the effective interest method. On January 5, 2026, the Company and the Administrative Agent entered into the First Amendment to Credit Agreement for certain cash management matters. The proceeds of the Credit Facility were or will be used for the working capital needs and general corporate …

DebtDisclosureTextBlock · excerpt; the full note is in the filing

The following table presents details regarding the composition of the Companys total revenue by product type for the years ended December 31, 2025, 2024, and 2023: Years Ended December 31, (In millions) 2025 2024 2023 Hereditary Cancer $ 372.4 $ 364.5 $ 327.8 Tumor Profiling 121.7 125.8 135.6 Prenatal 186.3 177.1 151.3 Mental Health 144.1 170.2 138.5 Total revenue $ 824.5 $ 837.6 $ 753.2 …

DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing

"STOCK-BASED COMPENSATION On November 30, 2017, the Companys stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the 2017 Plan). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee (the ""CHCC"") of the Board of Directors, to make grants of restricted and unrestricted stock and stock unit awards to employees, consultants and directors. Stockholders have subsequently approved amendments to the 2017 Plan increasing the shares available to grant thereunder, including most recently at the Company's annual meeting of stockholders held on June 5, 2025, when stockholders approved an amendment to the 2017 Plan to increase the aggregate number of shares of common stock available thereunder for the granting of awards by an additional 6.5 million shares. As of December 31, 2025, the Company had 5.3 million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. The number of shares, terms, and vesting periods are generally determined by the Companys Board of Directors or the CHCC on an award-by-award basis. RSUs granted to employees generally vest either ratably over three or four years or as cliff vesting after three years either on the annivers …

DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing

FAIR VALUE MEASUREMENTS The fair value of the Companys financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1quoted prices in active markets for identical assets and liabilities. Level 2observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3unobservable inputs. The carrying amounts of certain financial instrumentsincluding Cash and cash equivalents, Trade accounts receivable, Accounts payable, and Accrued expensesapproximate their fair values due to their short-term maturities. Additionally, the carrying value of the Company's Long-term debt as of December 31, 2025, approximates its fair value as the debts floating interest rate is consistent with prevailing market rates. The Company's fair value measurements related to impairment testing for goodwill and certain intangible assets were determined using Level 3 unobservable inputs; see Note 4. Goodwill and Intangible assets for further discussion. …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

GOODWILL AND INTANGIBLE ASSETS Goodwill The changes in the carrying amount of goodwill for the year ended December 31, 2025 are as follows: December 31, (in millions) 2025 Beginning balance $ 286.3 Goodwill impairment (234.7) Ending balance $ 51.6 During the quarter ended June 30, 2025, the Company identified a triggering event that required an interim goodwill impairment assessment. The Company experienced a sustained decline in its market capitalization, due in part to downward revisions to the Company's forecasts. In response to the triggering event, the Company estimated the fair values of each of its reporting units using both the market approach, applying an observable multiple of revenue based on guideline public companies, and the income approach, as of May 2025. The income approach considered projected revenue and profitability of each reporting unit and a discount rate reflective of the risk-adjusted cost of capital of 17.0% and 16.0% for the Mental Health and the Women's Health reporting units, respectively. The Company corroborated the reasonableness of the estimated reporting unit fair values by reconciling the values to its enterprise value and market capitalization, including the consideration of a control premium. Accordingly, this fair value measurement is classified as Level 3 in the fair value hierarchy because it is based primarily upon unobservable inputs that reflect management's assumptions. As a result of the assessment, during the quarter ended June 3 …

GoodwillAndIntangibleAssetsDisclosureTextBlock · excerpt; the full note is in the filing

"INCOME TAXES Income tax expense (benefit) consists of the following: Years Ended December 31, (in millions) 2025 2024 2023 Current: Federal $ (31.5) $ 3.4 $ 3.4 State 1.1 1.5 1.8 Foreign (0.2) 1.2 0.2 Total current (30.6) 6.1 5.4 Deferred: Federal (35.3) (15.5) (51.8) State (2.5) (5.5) (5.2) Foreign 0.4 3.1 0.1 Change in valuation allowance 38.8 15.6 52.6 Total deferred 1.4 (2.3) (4.3) Total income tax (benefit) expense $ (29.2) $ 3.8 $ 1.1 Loss before income taxes consists of the following: Years Ended December 31, (in millions) 2025 2024 2023 United States $ (394.6) $ (125.4) $ (263.2) Foreign (0.5) 1.9 1.0 Total $ (395.1) $ (123.5) $ (262.2) The table below provides the updated requirements of ASU 2023-09 for 2025. See Note 1 - Organization and Summary of Significant Accounting Policies - Recent accounting pronouncements for additional details on the adoption of ASU 2023-09. The effective income tax rate for the year ended December 31, 2025 differs from the statutory federal income tax rate as follows: Year Ended December 31, (in millions) 2025 Federal income tax benefit at the statutory rate (83.0) 21.0 % State and local income taxes, net of federal tax effect (1) 0.6 (0.1) % Foreign tax effects: Other foreign jurisdictions Statutory tax rate difference from United States 0.1 % Change in valuation allowance (0.4) 0.1 % Tax credits (2.5) 0.6 % Changes in valuation allowance 35.0 (8.9) % Nontaxable/nondeductible items: Incentive stock option and ESPP Expense 3.5 (0.9) % No …

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

LEASES The Company leases certain office spaces, research and development laboratory facilities, and office equipment with remaining lease terms ranging from approximately one to 13 years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options, which allow the Company, at its election, to renew or extend the lease for a fixed period of time. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases when the Company did not consider it reasonably certain it would exercise the options. The Company previously amended the lease for its West Salt Lake City facility to include approximately 63,000 additional square feet of laboratory space in anticipation of future operating needs. The lease has a term of 12 years and ends coterminous with the rest of the lease. The amendment commenced in fiscal year 2026 with future rent payments totaling $18.2 million. The majority of the Company's identified leases are operating leases. For the year ended December 31, 2025, the Company incurred $17.3 million in operating lease costs which are included in Operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $3.5 million was variable lease expense, which was not included in the measurement of the Company's operating ROU assets and lease liabil …

LesseeOperatingLeasesTextBlock · excerpt; the full note is in the filing

"Recent Accounting Pronouncements Recently Adopted Standards In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . ASU 2023-09 amends ASC 740, Income Taxes to expand income tax disclosures and requires that the Company disclose (i) the income tax rate reconciliation using both percentages and reporting currency amounts; (ii) specific categories within the income tax rate reconciliation; (iii) additional information for reconciling items that meet a quantitative threshold; (iv) the composition of state and local income taxes by jurisdiction; and (v) the amount of income taxes paid disaggregated by jurisdiction. The Company adopted ASU 2023-09 for the year ended December 31, 2025 on a prospective basis. See Note 9. Income Taxes for additional information. Standards Effective in Future Years and Not Yet Adopted In September 2025, the FASB issued ASU 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract. The guidance in ASU 2025-07 refines the scope of derivative accounting under ASC 815 by expanding an existing scope exception to exclude certain non-exchange traded contracts with underlyings based on the operations or activities of one of the contract parties from derivative clas …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

"SEGMENT AND RELATED INFORMATION The Companys business is aligned with how the Chief Operating Decision Maker (the ""CODM"") reviews performance and makes decisions in managing the Company. The Company has identified the President and Chief Executive Officer as the CODM. The CODM regularly reviews consolidated financial information for the purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. Accordingly, the Company has determined that it operates as a single operating segment. The Company has identified consolidated net income (loss) as the measure of segment profitability. The significant expenses and other segment expenses presented to the CODM are at the same level as presented in Consolidated Statement Operations in these financial statements. Substantially all of the Companys long-lived assets are located in the United States. Long-lived assets located outside the United States were not material for the periods presented."

SegmentReportingDisclosureTextBlock

PREFERRED AND COMMON STOCKHOLDERS' EQUITY The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no shares of preferred stock outstanding at December 31, 2025, and December 31, 2024. The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. In November 2023, the Company completed an underwritten public offering in which it sold 7.4 million shares of its common stock at a price of $17.00 per share, for gross proceeds of $126.5 million and net proceeds of $117.6 million. There were 93.5 million and 91.3 million shares of common stock issued and outstanding at December 31, 2025, and 2024, respectively. Shares of common stock issued and outstanding Years Ended December 31, (in millions) 2025 2024 2023 Beginning common stock issued and outstanding 91.3 89.9 81.2 Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans 2.2 1.4 1.3 Common stock issued for public offering 7.4 Common stock issued and outstanding at end of period 93.5 91.3 89.9 …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing

COMMITMENTS AND CONTINGENCIES The Company is involved from time to time in various disputes, claims, and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amounts of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding its business which may result in adverse judgments, settlements, fines, penalties, injunctions, or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company has received subpoenas from time to time related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations, or other laws. The Company intends to defend its current litigation matters but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows. The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accru …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

"LONG-TERM DEBT The Company's long-term debt at June 30, 2026 and December 31, 2025 consisted of the following amounts: (in millions) June 30, 2026 December 31, 2025 Long-term debt $ 125.0 $ 125.0 Accrued exit fee 3.8 3.8 Unamortized debt discount and issuance costs (8.1) (8.9) Total long-term debt, net $ 120.7 $ 119.9 On July 31, 2025 (the ""Closing Date""), the Company entered into a Credit Agreement (the ""Credit Agreement"") with the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent (the ""Administrative Agent"") and as initial lender. The Credit Agreement consists of a $200.0 million term loan credit facility with an initial term loan of $125.0 million (the ""Initial Loan""), which amount was funded on the Closing Date, and delayed draw term loans (the ""Delayed Draw Loans"" and together with the Initial Loan, the ""Loans""), at the election of the Company, subject to the timing and terms specified in the Credit Agreement, on or prior to June 30, 2027, in a maximum principal amount of $75.0 million (collectively, the ""Credit Facility""). The Company incurred debt discounts and issuance costs totaling $9.4 million. These costs are being amortized using the effective interest method. The proceeds of the Credit Facility were used to repay and terminate the Company's previous borrowing, with the remainder designated for working capital needs and general corporate purposes. On January 5, 2026, the Company …

DebtDisclosureTextBlock · excerpt; the full note is in the filing

The following table presents details regarding the composition of the Companys total revenue by product type and by geographical region, either U.S. or rest of world (RoW): Three Months Ended June 30, 2026 2025 (in millions) U.S. RoW Total U.S. RoW Total Cancer Care Continuum $ 100.9 $ 13.2 $ 114.1 $ 112.9 $ 14.8 $ 127.7 Prenatal Health 39.8 39.8 47.5 0.1 47.6 Mental Health 36.8 36.8 37.8 37.8 Total revenue $ 177.5 $ 13.2 $ 190.7 $ 198.2 $ 14.9 $ 213.1 Six months ended June 30, 2026 2025 (in millions) U.S. RoW Total U.S. RoW Total Cancer Care Continuum $ 207.7 $ 26.6 $ 234.3 $ 214.3 $ 29.0 $ 243.3 Prenatal Health 81.7 81.7 96.7 0.2 96.9 Mental Health 75.1 75.1 68.8 68.8 Total revenue $ 364.5 $ 26.6 $ 391.1 $ 379.8 $ 29.2 $ 409.0 …

DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing

"STOCK-BASED COMPENSATION On June 4, 2026, the Company's stockholders approved the adoption of the 2026 Employee, Director and Consultant Equity Incentive Plan (the ""2026 Plan"") which replaced the 2017 Employee, Director and Consultant Equity Incentive Plan (the ""2017 Plan"") as the Company's equity incentive plan for future awards. The 2026 Plan allows the Company, under the direction of the Compensation and Human Capital Committee (the ""CHCC"") of the Company's Board of Directors, to make grants of stock options, stock grants, and stock-based awards, including restricted stock unit awards and stock appreciation rights, to employees, consultants and directors. The 2026 Plan provides for the issuance of up to approximately 8.5 million shares of common stock, which includes shares of common stock that were available for future grants under the 2017 Plan as of June 4, 2026. In addition, any shares subject to awards granted under the 2017 Plan that are forfeited, expire, or are cancelled without the delivery of shares on or after June 4, 2026, up to an aggregate maximum of approximately 8.7 million shares of common stock, will become available for issuance under the 2026 Plan. Following stockholder approval of the 2026 Plan, no further awards will be granted under the 2017 Plan, although outstanding awards under the 2017 Plan remain in effect subject to the terms of the 2017 Plan and the individual awards. As of June 30, 2026, the Company had 5.8 million shares of common sto …

DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing

"FAIR VALUE MEASUREMENTS The fair value of the Companys financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1quoted prices in active markets for identical assets and liabilities. Level 2observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Companys marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities. Level 3unobservable inputs. The carrying amounts of certain financial instrumentsincluding cash and cash equivalents, accounts receivable, accounts payable, and accrued expensesapproximate their fair values due to their short-term maturities. Additionally, the carrying value of our long-term debt as of June 30, 2026, approximates its fair value due to the debts floating interest rate based on prevailing market rates. The Company's fair value measurements related to impairment testing for goodwill and certain intangible assets were determine …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

GOODWILL AND INTANGIBLE ASSETS Goodwill The change in the carrying amount of goodwill for the six months ended June 30, 2026 is as follows: (in millions) Total Beginning balance $ 51.6 Goodwill impairment (4.5) Ending balance $ 47.1 A sustained decline in the Company's share price and market capitalization during the first quarter of 2026 was identified as a triggering event requiring an interim goodwill impairment test. As a result, the fair value of each reporting unit was estimated as of March 31, 2026 using the market approach, based on observable revenue multiples of guideline public companies, and the income approach. The income approach considered projected revenue and profitability of each reporting unit and a discount rate reflective of the risk-adjusted cost of capital of 17% for the Women's Health reporting unit. The Company corroborated the reasonableness of the estimated reporting unit fair values by reconciling the values to the Company's enterprise value and market capitalization, including the consideration of a control premium. Accordingly, this fair value measurement is classified as Level 3 in the fair value hierarchy because it is based primarily upon unobservable inputs that reflect management's assumptions. As a result of the impairment test, during the three months ended March 31, 2026, the Company recognized a goodwill impairment charge of $4.5 million attributable to the Women's Health reporting unit, reducing the carrying value of goodwill for the re …

GoodwillAndIntangibleAssetsDisclosureTextBlock · excerpt; the full note is in the filing

INCOME TAXES In order to determine the Companys quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter. For the three months ended June 30, 2026, income tax expense was $0.6 million, or approximately (1.4)% of pre-tax loss, compared to $0.1 million income tax benefit, or approximately 0.0% of pre-tax loss, for the three months ended June 30, 2025. For the six months ended June 30, 2026, income tax expense was $0.6 million, or approximately (0.78)% of pre-tax loss, compared to an income tax benefit of $29.4 million, or approximately 8.2% of pre-tax loss, for the six months ended June 30, 2025. For the three and six months ended June 30, 2026, the Companys effective tax rate differs from the U.S. federal statutory rate primarily due to the recognition of valuation allowances. Due to the Company's cumulative loss and the exhaustion of future taxable income from the reversal of taxable temporary differences, the Company's estimated annual effective tax rate for the current year includes a valuation allowance against the current year increase in deferred tax assets. For the three months ended June 30, 2025, the Companys effective tax rat …

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

LEASES The Company leases certain office spaces, research and development laboratory facilities, and office equipment with remaining lease terms ranging from approximately one to twelve years. Operating leases are included in Operating lease right-of-use assets, Noncurrent operating lease liabilities, and Current maturities of operating lease liabilities in the Condensed Consolidated Balance Sheets. Finance leases are included in Other assets, Accrued liabilities, and Other long-term liabilities in the Condensed Consolidated Balance Sheets. The Company previously amended the lease for its west Salt Lake City headquarters in 2024 to expand the facility in anticipation of future operating needs. During the six months ended June 30, 2026, the Company took possession of the remaining square footage of the west Salt Lake City facility and recognized an additional $2.7 million right-of-use asset and corresponding lease liability, net of a tenant improvement allowance not yet received of approximately $6.5 million. Future rent payments associated with the expanded space are approximately $18.2 million.

LesseeOperatingLeasesTextBlock

"Recent Accounting Pronouncements In September 2025, the Financial Accounting Standards Board (""FASB"") issued Accounting Standards Update (""ASU"") 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract. The guidance in ASU 2025-07 refines the scope of derivative accounting under Accounting Standards Codification (""ASC"") 815 by expanding an existing scope exception to exclude certain non-exchange traded contracts with underlyings based on the operations or activities of one of the contract parties from derivative classification. ASU 2025-07 also provides guidance under Topic 606 on the accounting for share-based noncash consideration received from a customer in a revenue contract, including measurement and timing considerations. ASU 2025-07 is effective for annual and interim periods beginning after December 15, 2026, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-07. In September 2025, the FASB issued ASU 2025-06, Targeted Improvements to the Accounting for Internal-Use Software , which amends certain aspects of the accounting for and disclosure of software costs under ASC 350-40, Internal-Use Software Accounting & Capitalization . ASU 2025-06 makes targeted modifications to ASC 350-40 by changing the cost capitalization threshold, eliminating …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

REVENUE The Company primarily generates revenue by performing molecular diagnostic testing, primarily derived from the following categories of products: Cancer Care Continuum (MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris + AI, Precise Tumor, and Precise MRD), Prenatal Health (Foresight, Prequel, FirstGene and SneakPeek), and Mental Health (GeneSight). Certain products previously presented within separate Hereditary Cancer and Tumor Profiling categories during the prior year periods are now collectively reported within the Cancer Care Continuum category. Revenue is recorded at the estimated transaction price. Control is transferred and revenue is recognized once test results are released to the healthcare provider and/or patient. The following table presents details regarding the composition of the Companys total revenue by product type and by geographical region, either U.S. or rest of world (RoW): Three Months Ended June 30, 2026 2025 (in millions) U.S. RoW Total U.S. RoW Total Cancer Care Continuum $ 100.9 $ 13.2 $ 114.1 $ 112.9 $ 14.8 $ 127.7 Prenatal Health 39.8 39.8 47.5 0.1 47.6 Mental Health 36.8 36.8 37.8 37.8 Total revenue $ 177.5 $ 13.2 $ 190.7 $ 198.2 $ 14.9 $ 213.1 Six months ended June 30, 2026 2025 (in millions) U.S. RoW Total U.S. RoW Total Cancer Care Continuum $ 207.7 $ 26.6 $ 234.3 $ 214.3 $ 29.0 $ 243.3 Prenatal Health 81.7 81.7 96.7 0.2 96.9 Mental Health 75.1 75.1 68.8 68.8 Total revenue $ 364.5 $ 26.6 $ 391.1 $ 379.8 $ 29.2 $ 409.0 In determining the …

RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing

"SEGMENT REPORTING AND RELATED INFORMATION The Company has identified its President and Chief Executive Officer as its Chief Operating Decision Maker (the ""CODM""). The CODM regularly reviews consolidated financial information for the purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. In alignment with how the CODM reviews performance and makes decisions in managing the Company, the Company has determined that it operates as a single operating segment. The Company has identified consolidated net income (loss) as the measure of segment profitability. The significant expenses and other segment expenses presented to the CODM are at the same level as presented in the Condensed Consolidated Statements of Operations."

SegmentReportingDisclosureTextBlock

PREFERRED AND COMMON STOCKHOLDERS' EQUITY The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no shares of preferred stock outstanding at June 30, 2026. The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 95.6 million shares of common stock issued and outstanding at June 30, 2026. Shares of Common Stock Issued and Outstanding A summary of the changes in the issued and outstanding common stock for the six months ended June 30, 2026 and 2025 is as follows: Six months ended June 30, (in millions) 2026 2025 Beginning common stock issued and outstanding 93.5 91.3 Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan, net of shares exchanged for withholding tax 2.1 1.8 Common stock issued and outstanding at end of period 95.6 93.1 Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an anti-dilutive effect. The following is a reconciliation of the denominators of the basic and diluted earnings per sh …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing